Real-world treatment of metastatic hormone-sensitive prostate cancer in the USA, Europe and Asia.
Future Oncol
; 20(14): 903-918, 2024 May.
Article
em En
| MEDLINE
| ID: mdl-38353055
ABSTRACT
Aim:
To characterize real-world patients with metastatic hormone-sensitive prostate cancer (mHSPC) and treating physicians and evaluate treatment trends and baseline concordance versus guidelines internationally. Materials &methods:
Retrospective, cross-sectional data from the Ipsos Global Oncology Monitor database 2018-2020 were used for descriptive analysis of mHSPC patients, treating physicians and treatment utilization.Results:
Among the 6198 mHSPC patients from five countries, the most common treatment was either androgen deprivation therapy (ADT) monotherapy or first-generation androgen receptor inhibitor + ADT. Second-generation androgen receptor inhibitor use was only initiating but increasing over the study period.Conclusion:
Despite contemporaneous guidelines recommending treatment intensification of ADT in combination with novel antihormonals or docetaxel, 76.1% of reported mHSPC patients received non-guideline-concordant care.
Prostate cancer is the second most common cancer among men worldwide and a leading cause of cancer-related death globally. Metastatic hormone-sensitive prostate cancer (mHSPC) refers to the stage of prostate cancer where it has spread to other parts of the body ('metastatic') but still responds to hormonal therapy ('hormone-sensitive'), such as androgen deprivation therapy (ADT). Treatment guidelines around the world for men with mHSPC have changed over time, but there remains a lack of understanding of how well guidelines are followed in real-world practice. Consequently, this study analyzes real-world data from five countries between 2018 and 2020 to understand treatment patterns, baseline concordance versus guidelines and potential drivers of treatment trends. The study found prevalent use of ADT monotherapy and older antihormonal agents, and only marginal but increasing use of novel antihormonals in real-world practice. These practices deviate from guidelines from the study period, which generally recommended ADT combination with either newer antihormonal agents or docetaxel for patients with mHSPC. Overall, the proportion of the 6198 patients treated with nonguideline-concordant therapies was 76.1%. Since guideline-recommended care is associated with better outcomes, this baselining finding highlights the need for appropriate treatment selection and intensification for mHSPC patients.
Palavras-chave
androgen antagonists, therapeutic use; antineoplastic agents, hormonal, therapeutic use; antineoplastic combined chemotherapy protocols, therapeutic use; guideline adherence; health care surveys, trends; neoplasm metastasis; practice guidelines as topic; practice patterns, physicians' trends; prostatic neoplasms, drug therapy; prostatic neoplasms, pathology
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Próstata
Tipo de estudo:
Diagnostic_studies
/
Guideline
Limite:
Humans
/
Male
Idioma:
En
Revista:
Future Oncol
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
Alemanha